Conformal Medical said today that it raised $9 million in a Series B round for the anti-stroke cardiac implant it’s developing.
Nashua, N.H.-based Conformal is working on a left atrial appendage seal to prevent stroke in atrial fibrillation patients. It’s designed to adapt to the each patient’s individual physiology, to be easier to implant with less imaging and without general anesthesia.
The funding round was led by Catalyst Health Ventures and included “a supportive group of Series A investors,” Conformal said.
“This financing will allow us to validate our novel sealing technology in human trials,” CEO Andy Levine said in prepared remarks. “We are pleased to have Catalyst join our strong investor base, which continues to reflect confidence in our approach to treating this serious medical condition.”
“LAA closure is changing our approach to stroke reduction for AFib patients,” added Dr. William Gray, of Philadelphia’s Main Line Health. “First-generation devices have limitations. The novel Conformal system is designed to be easier to deliver and provide a better seal, as has been borne out in pre-clinical studies. These advances should allow us to treat a larger spectrum of patients.”
“We are thrilled to join this exciting company as they bring the Conformal device through the clinic and to market,” Catalyst managing partner Josh Phillips said. “This technology promises to bring significant benefit to the large population of patients with atrial fibrillation.”
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.